GS
69
-3
XOM
54
3
ZION
55
2
WDC
49
-4
FMC
31
-3
MRO
50
11
KIM
51
4
FSLR
76
3
PSA
48
2
NKE
39
2
TSN
38
-2
AIV
62
-2
MPC
44
5
AVY
77
2
GOOG
75
2
RSG
67
2
AVGO
57
-4
HBI
62
7
FRT
53
3
FCX
67
14
GS
69
-3
XOM
54
3
ZION
55
2
WDC
49
-4
FMC
31
-3
MRO
50
11
KIM
51
4
FSLR
76
3
PSA
48
2
NKE
39
2
TSN
38
-2
AIV
62
-2
MPC
44
5
AVY
77
2
GOOG
75
2
RSG
67
2
AVGO
57
-4
HBI
62
7
FRT
53
3
FCX
67
14
Financhill
Back

Lexicon Pharmaceuticals 10K Form

Buy
51

LXRX
Lexicon Pharmaceuticals

Last Price:
1.80
Seasonality Move:
4.85%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LXRX News And Ratings

See the #1 stock for the next 7 days that we like better than LXRX

LXRX Financial Statistics

Sales & Book Value

Annual Sales: $1.2M
Cash Flow: $-55.13M
Price / Cash Flow: 0
Annual Sales: $1.17
Price / Book: 2.22

Profitability

EPS (TTM): -0.83000
Net Income (TTM): $-193.58M
Gross Margin: $1.12M
Return on Equity: -121.61%
Return on Assets: -69.01%

Lexicon Pharmaceuticals Earnings Forecast

Key Lexicon Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 25 years for LXRX is 92.94%.
  • The Selling, General & Administrative Expenses for LXRX have been equal to 9,466.94% of Gross Profit Margin.
  • The Research & Development expenses have been 4,890.95% of Revenue.
  • The Interest Expense is -7.40% of Operating Income.
  • The Net Earning history of LXRX is -14,710.88% of Total Revenues.
  • Per Share Earnings over the last 25 years have been positive in 13 years.

Lexicon Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: LXRX
CUSIP: 528872
Website: lexpharma.com

Debt

Debt-to-Equity Ratio: 0.35
Current Ratio: 15.58
Quick Ratio: 15.26

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

LXRX Technical Analysis vs Fundamental Analysis

Buy
51
Lexicon Pharmaceuticals (LXRX) is a Buy

Is Lexicon Pharmaceuticals a Buy or a Sell?